


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-16.43%
+4.10%
-1.04%
+77.43%
-2.62%
CRSP
CRISPR Therapeutics
$53.98
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Outperform the market
CRSP Price Performance
$54.65 (-1.23%)
$53.57 (+0.77%)
$63.62 (-15.15%)
$43.34 (+24.55%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Investors confidence is positive
Future
Future
Earnings are forecast to grow
Trading below its fair value
Outperform the market
CRSP Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
CRSP Street Sentiment is extremely bullish and have positive views on the near-term outlook
CRSP has Fair risk level
Risk Indicators
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Dec 31, 2025
Reiterate
Buy
Chardan
Dec 24, 2025
Reiterate
Buy
Needham
Dec 24, 2025
Reiterate
Outperform
Citizens
Nov 13, 2025
Reiterate
Buy
Citigroup
Oct 17, 2025
Reiterate
Buy
B of A Securities
IBRX
ImmunityBio
9.83
+12.99%
CLDI
Calidi Biotherapeutics In
0.75
-4.85%
BNTX
BioNTech
109.93
-0.20%
BEAM
Beam Therapeutics In
28.33
+2.68%
What is CRSP current stock price?
What are CRSP stock strengths?
What is CRSP Risk Level?
What is CRSP market cap and volume?
What is CRSP current Stock IQ?
Should I buy CRSP stock right now?
Is CRSP a Strong Buy right now?
What does a 'Strong Buy' rating mean for CRSP?
What does a 'Strong Sell' rating mean for CRSP?
What factors influence CRSP's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
CRSP
CRISPR Therapeutics
Current Price
$53.98
Runners Also Watch
IBRX
ImmunityBio
9.83
+12.99%
CLDI
Calidi Biotherapeutics In
0.75
-4.85%
BNTX
BioNTech
109.93
-0.20%
BEAM
Beam Therapeutics In
28.33
+2.68%

CRSP Price Performance
$54.65 (-1.23%)
$53.57 (+0.77%)
$63.62 (-15.15%)
$43.34 (+24.55%)
CRSP Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Investors confidence is positive
Future
Future
Earnings are forecast to grow
Trading below its fair value
Outperform the market
CRSP Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
CRSP Street Sentiment is extremely bullish and have positive views on the near-term outlook
CRSP has Fair risk level
Risk Indicators
Average key support and resistance price levels
Overall Wall Street Rating
CRSP Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Outperform the market
CRSP Latest Analysis
CRISPR Therapeutics AG (CRSP) Presents at Citis 2026 Virtual Oncology Leadership Summit Transcript.
Wed Feb 18, 2026
Should You Buy Shares of CRISPR Therapeutics in February?. Key PointsCasgevy is starting to build some serious sales momentum.
Wed Feb 18, 2026
Can a CRISPR blood test spot cancer early? #science. A light based CRISPR sensor aims for earlier detection Researchers have combined CRISPR molecular recognition with an ultrasensitive light readout to build a blood test that can detect minute molecular signs of cancer in a single drop of blood. The platform uses the sequence specific targeting of
Wed Feb 18, 2026
Crispr: Emphasis Shifts To Cardiovascular Pipeline Amid Slow Casgevy Launch.
Tue Feb 17, 2026
CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027.
Tue Feb 17, 2026
How does the CRISPR blood test detect cancer early? #science. A new highly sensitive diagnostic approach Researchers have developed a CRISPR powered light sensor that can pick up extremely faint molecular signals of cancer from a single drop of blood. The device combines the sequence targeting power of CRISPR enzymes with a light producing readout
Tue Feb 17, 2026
Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss). Key PointsCRISPR Therapeutics&rsquo. fourth quarter was relatively disappointing.
Fri Feb 13, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CRSP Stock trends
CRSP Stock performance
CRSP Stock analysis
CRSP investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.